by 
Oligonucleotides Market Key Takeaways
- In terms of revenue, the global oligonucleotides market was valued at USD 4.23 billion in 2024.
- It is projected to reach USD 14.54 billion by 2034.
- The market is expected to grow at a CAGR of 13.14% from 2025 to 2034.
- North America dominated the oligonucleotides market in 2024.
- By region, Asia Pacific is anticipated to witness the fastest growth during the forecasted years.
- By product type, the therapeutic oligonucleotides segment held a significant share in 2024.
- By product type, the diagnostic oligonucleotides segment is anticipated to show considerable growth over the forecast period.
- By application, the drug discovery & development segment captured the biggest market share in 2024.
- By application, the RNA-based therapeutics segment is anticipated to show considerable growth over the forecast period.
- By manufacturing technology, the solid phase oligonucleotide synthesis segment contributed the highest market share in 2024.
- By manufacturing technology, the microarray-based synthesis segment is anticipated to show considerable growth over the forecast period.
- By end-user, the pharmaceutical and biotechnology companies segment generated the major market share in 2024.
- By end-user, the contract manufacturing organizations segment is anticipated to show considerable growth over the forecast period.
- By sales channel, the direct sales segment held the largest market share in 2024.
- By sales channel, the online platforms segment is anticipated to show considerable growth over the forecast period.
- By delivery mode, the injectable segment accounted for remarkable market share in 2024.
- By delivery mode, the intranasal segment is anticipated to show considerable growth over the forecast period.
How AI Integration Is Transforming the Oligonucleotides Market
Artificial Intelligence (AI) is playing a transformative role in the oligonucleotides market by accelerating research, enhancing design precision, and streamlining therapeutic development. Advanced AI algorithms enable rapid identification and optimization of target-specific oligonucleotides during the early stages of drug discovery, significantly reducing both time and costs. In clinical development, AI-driven analytics support patient stratification, paving the way for more effective and personalized treatment strategies. Furthermore, integration with bioinformatics platforms enhances data interpretation and fosters real-time communication across clinical teams, enabling faster and more informed decision-making. As AI technologies continue to evolve, they are expected to drive innovation and efficiency across the entire oligonucleotide development pipeline
Market Overview
The oligonucleotides market encompasses short, synthetic strands of DNA or RNA—typically 15 to 25 nucleotides in length used in a wide range of life sciences, diagnostics, and therapeutic applications. These molecules are essential tools in gene expression analysis, antisense therapy, PCR, next-generation sequencing (NGS), molecular diagnostics, and targeted drug delivery. As personalized medicine, molecular diagnostics, and RNA-based therapeutics gain traction, oligonucleotides have become foundational to modern biotechnology and pharmaceutical innovation.
Market growth is being driven by the rising demand for personalized treatments, increasing prevalence of genetic disorders, and the rapid development of RNA-based drugs. Technological advancements in oligonucleotide synthesis and delivery systems have significantly improved their stability, specificity, and therapeutic efficacy, broadening their utility in clinical and research settings. Additionally, increased public and private investment in genomics and
hat Factors Are Fueling the Rapid Expansion of the Oligonucleotides Market?
- Developments in Personalized Medicine and Gene Therapy: Antisense and RNA-based technologies are finding their way more frequently in the targeted therapy of cancers and rare genetic diseases. This tendency corresponds to the movement towards the precision medicine field, which has increased the need for oligonucleotides in clinical practices and the scope to treat some complex, gene-related diseases.
- Increasing Numbers of Genetic and Chronic Diseases: The rising cases of genetic disorders, cancer, and chronic diseases have boosted the demand for accurate diagnosis and treatment instruments. The specificity of gene targeting using oligonucleotides is critical to the achievement of a particular outcome, thus increasing the value of oligonucleotides in the creation of disease-molecular-based treatments.
- Innovations in Oligonucleotide Synthesis: The advances in synthesis and automation have made oligonucleotide production more scalable, high-purity, and cost-effective. Such advances facilitate the use in therapeutics and diagnostics, expanding the possibility of the use of oligonucleotide-based solutions to research institutions and pharmaceutical companies and enhancing the growth of the market.
Opportunity
Rapid Adoption of Antisense Oligonucleotides (ASOs)
The growing acceptance of antisense oligonucleotides (ASOs) as targeted anticancer agents presents a significant opportunity for the oligonucleotides market. ASOs function by selectively binding to messenger RNA (mRNA) sequences, allowing for the silencing of specific oncogenes or mutated genes involved in tumor development. This high level of specificity offers a more precise alternative to traditional chemotherapy and radiation therapies, reducing off-target effects and improving treatment outcomes.
Ongoing research, supportive regulatory frameworks, and increased investment in RNA-based therapies are accelerating the clinical advancement and adoption of ASOs. As oncology increasingly shifts toward personalized, gene-targeted approaches, ASOs are emerging as a critical component in the evolving landscape of cancer treatment.
Regional Insights
Why Did North America Dominate the Oligonucleotides Market in 2024?
North America held the largest share of the oligonucleotides market in 2024, driven by its strong pharmaceutical and biotechnology sectors, advanced research infrastructure, and growing demand for innovative therapeutic and diagnostic solutions. The region benefits from a favorable regulatory landscape and substantial investment opportunities that support the acceleration of clinical trials and the commercialization of oligonucleotide-based therapies.
The United States, in particular, emerged as the leading contributor within North America. As a global hub for genomic research, biotechnology innovation, and therapeutic development, the U.S. boasts significant R&D investments and an extensive focus on personalized medicine, molecular diagnostics, and gene-editing technologies such as CRISPR. The rising prevalence of cancer and genetic disorders in the country continues to drive the demand for advanced, targeted treatment options, positioning the U.S. as a key market for oligonucleotide innovation.
Why Is the Asia Pacific Region Expected to Grow at the Fastest CAGR?
Asia Pacific is projected to witness the highest compound annual growth rate (CAGR) in the oligonucleotides market during the forecast period. This growth is fueled by increasing efforts from global industry leaders to tap into emerging markets with high growth potential. Countries such as China, Japan, and India are at the forefront of this regional expansion, making significant advancements in oligonucleotide synthesis, molecular diagnostics, and gene-based therapeutics.
The region is experiencing rapid growth in genomics research and widespread adoption of technologies like PCR and next-generation sequencing. Government support, improved healthcare infrastructure, and rising public and private investments in biotechnology further propel market growth. In China, strategic government initiatives are promoting investment in genomics and personalized medicine, boosting demand for oligonucleotides in the development of advanced diagnostics and targeted treatments. Additionally, increased collaboration between local and international biotech companies is accelerating technology transfer and making cutting-edge oligonucleotide synthesis technologies more widely accessible across the region.
Recent Developments
- In February 2025, Jawaharlal Nehru India Centre for Advanced Scientific Research organized the first Nucleic Acid Therapeutics Regional Meeting. The conference encouraged industry- and academic-based research in the formation of oligonucleotide therapeutics.
- In January 2025, Maravai LifeSciences purchased pertinent property and intellectual rights of Molecular Assemblies (MAI). The technology, Fully Enzymatic Synthesis (owned by Molecular Assemblies), will upgrade oligonucleotides and mRNA production functions at TriLink BioTechnologies.
- In December 2024, Co-Dx with CoSara Diagnostics Pvt. Ltd commissioned an oligonucleotide synthesis facility in Ranoli, India. In line with the Make in India program, the factory will produce Co-Primers oligos in-house.
Oligonucleotides Market Key Players
- Ionis Pharmaceuticals
- Alnylam Pharmaceuticals
- Bio-Synthesis Inc.
- Thermo Fisher Scientific
- Eurofins Genomics
- Integrated DNA Technologies (IDT)
- Biogen
- Sarepta Therapeutics
- Nitto Denko (Nitto Avecia)
- Bioneer Corporation
- LGC Biosearch Technologies
- GE Healthcare
- TriLink BioTechnologies
- Bio-Techne Corporation
- Exiqon (QIAGEN)
- GeneDesign, Inc.
- Agilent Technologies
- Roche Diagnostics
- AstraZeneca (via Ionis collaborations)
- GenScript Biotech Corporation
